Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:32 ET | 10514 | 0.8204 |
09:34 ET | 500 | 0.8341 |
09:36 ET | 100 | 0.8312 |
09:38 ET | 8457 | 0.82 |
09:39 ET | 334 | 0.834199 |
09:41 ET | 1434 | 0.8342 |
09:43 ET | 900 | 0.8343 |
09:45 ET | 2500 | 0.8342 |
09:48 ET | 25576 | 0.8251 |
09:50 ET | 4716 | 0.8251 |
09:52 ET | 300 | 0.8251 |
09:54 ET | 100 | 0.834 |
09:56 ET | 250 | 0.825 |
09:59 ET | 290 | 0.826001 |
10:01 ET | 600 | 0.826 |
10:03 ET | 2900 | 0.8255 |
10:06 ET | 1802 | 0.8254 |
10:08 ET | 700 | 0.8209 |
10:10 ET | 1016 | 0.8209 |
10:12 ET | 280 | 0.8209 |
10:19 ET | 340 | 0.8332 |
10:24 ET | 750 | 0.841 |
10:26 ET | 215 | 0.8209 |
10:28 ET | 1520 | 0.8409 |
10:35 ET | 400 | 0.831349 |
10:39 ET | 279 | 0.826901 |
10:42 ET | 266 | 0.8227 |
10:44 ET | 1000 | 0.8227 |
10:48 ET | 1000 | 0.826999 |
10:53 ET | 1991 | 0.8301 |
10:57 ET | 297 | 0.8386 |
11:00 ET | 250 | 0.834351 |
11:04 ET | 200 | 0.8342 |
11:06 ET | 100 | 0.8344 |
11:11 ET | 198 | 0.8344 |
11:20 ET | 1000 | 0.8337 |
11:22 ET | 100 | 0.8331 |
11:24 ET | 1250 | 0.8346 |
11:27 ET | 4063 | 0.833 |
11:33 ET | 889 | 0.8489 |
11:38 ET | 100 | 0.8416 |
11:42 ET | 100 | 0.8417 |
11:45 ET | 100 | 0.8468 |
11:54 ET | 250 | 0.8452 |
11:56 ET | 3158 | 0.8421 |
11:58 ET | 1700 | 0.84 |
12:00 ET | 900 | 0.8415 |
12:05 ET | 100 | 0.8334 |
12:07 ET | 217 | 0.83745 |
12:09 ET | 100 | 0.8415 |
12:12 ET | 111 | 0.8415 |
12:14 ET | 2100 | 0.8343 |
12:25 ET | 267 | 0.835 |
12:32 ET | 100 | 0.8451 |
12:34 ET | 1750 | 0.837061 |
12:36 ET | 400 | 0.8372 |
12:41 ET | 360 | 0.8371 |
12:45 ET | 1325 | 0.84 |
12:48 ET | 1504 | 0.8344 |
12:54 ET | 262 | 0.8416 |
01:01 ET | 100 | 0.8487 |
01:06 ET | 300 | 0.8488 |
01:10 ET | 100 | 0.8432 |
01:14 ET | 100 | 0.8461 |
01:19 ET | 343 | 0.84 |
01:21 ET | 700 | 0.84 |
01:26 ET | 250 | 0.8416 |
01:28 ET | 463 | 0.8343 |
01:30 ET | 5065 | 0.8344 |
01:33 ET | 500 | 0.8344 |
01:39 ET | 300 | 0.8344 |
01:48 ET | 1595 | 0.8343 |
01:50 ET | 200 | 0.8437 |
01:51 ET | 11578 | 0.8301 |
01:57 ET | 5000 | 0.8301 |
02:08 ET | 7832 | 0.83 |
02:13 ET | 1791 | 0.8269 |
02:26 ET | 5000 | 0.82701 |
02:27 ET | 900 | 0.827 |
02:31 ET | 215 | 0.827 |
02:49 ET | 400 | 0.83 |
03:00 ET | 1496 | 0.83 |
03:02 ET | 730 | 0.8427 |
03:05 ET | 5000 | 0.830101 |
03:09 ET | 500 | 0.842749 |
03:12 ET | 400 | 0.843 |
03:14 ET | 100 | 0.8555 |
03:16 ET | 466 | 0.8489 |
03:21 ET | 100 | 0.8555 |
03:30 ET | 100 | 0.8555 |
03:32 ET | 3640 | 0.842751 |
03:34 ET | 1906 | 0.83 |
03:36 ET | 2661 | 0.8514 |
03:43 ET | 1287 | 0.8301 |
03:45 ET | 12239 | 0.8227 |
03:48 ET | 100 | 0.8201 |
03:52 ET | 31500 | 0.803 |
03:54 ET | 750 | 0.801 |
03:56 ET | 7674 | 0.80095 |
03:57 ET | 1977 | 0.80095 |
03:59 ET | 3072 | 0.801 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 37.4M | -2.3x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
CASI Pharmaceuticals Inc | 47.8M | -1.5x | --- |
Biofrontera Inc | 5.3M | -0.1x | --- |
Health-Chem Corp | 1.2K | 0.0x | --- |
Bon Natural Life Ltd | 9.9M | 0.4x | +78.05% |
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $37.4M |
---|---|
Revenue (TTM) | $37.9M |
Shares Outstanding | 35.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.92 |
EPS | $-0.35 |
Book Value | $0.64 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | 1.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -34.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.